1. Introduction {#sec1}
===============

Gastric cancer is the fifth most common malignant tumor and the third leading cause of cancer death in the world and has become a major global health problem due to high morbidity and mortality \[[@B1], [@B2]\]. Although the incidence and mortality of gastric cancer have declined in the last decade, it is still the third most common cause of cancer death in Chinese men and the second most common cause of cancer in Chinese women \[[@B3]\]. Currently, surgery is still the main treatment for gastric cancer, but the survival rate of patients with gastric cancer is lower than 30% \[[@B4]\]. Recurrence or metastasis will occur in approximately 35--70% patients within 5 years, even after radical resection \[[@B5]\]. To reduce the risk of postoperative recurrence and metastasis, early diagnosis and developing an appropriate treatment plan based on the expected survival time of patients will help improve the cure rate of gastric cancer and the survival quality of patients. At present, clinicians mainly evaluate the prognosis of patients with gastric cancer according to the 8^th^ edition of the American Joint Committee on Cancer tumor node metastasis (AJCC-TNM) staging system. However, the prognosis of patients with gastric cancer within the same TNM stage is usually different after receiving similar treatment \[[@B6]\]. Therefore, further studies are needed to identify new tumor markers with high specificity and sensitivity in gastric cancer and to distinguish patient subgroups with a high risk of recurrence and metastasis to accurately predict the prognosis of patients with gastric cancer and determine the optimal therapeutic strategy.

Tumor-related inflammation plays an important role in the occurrence and development of tumors, and immune and inflammatory cells are considered important components in the tumor microenvironment \[[@B7]\]. Immune and inflammatory cells in peripheral blood, such as neutrophils, monocytes, platelets, and lymphocytes, are believed to lead to invasion and metastasis of tumor cells, which have close correlations with the progression of a variety of tumors \[[@B8]--[@B10]\]. Some indexes of the above inflammatory cells, such as the neutrophil-lymphocyte ratio (NLR), platelet-lymphocyte ratio (PLR), and monocyte-lymphocyte ratio (MLR), have become prognostic factors for various cancers and are used to predict survival and recurrence of cancers, including gastric cancer \[[@B11]--[@B14]\]. Recently, the systemic immune-inflammation index (SII), based on peripheral lymphocytes, neutrophils, and platelet count, has been used to better reflect the balance between host inflammation and immune status; its prognostic value in hepatocellular carcinoma \[[@B15], [@B16]\], oesophageal cancer \[[@B17]\], colorectal cancer \[[@B18]\], and small cell lung cancer \[[@B19]\] has been confirmed, but its value in gastric cancer remains unclear. In this study, the prognostic value of SII for gastric cancer patients who underwent radical surgery was evaluated, and the prognostic nomogram of resectable gastric cancer was plotted and compared with the traditional AJCC-TNM staging system to determine whether the model can evaluate the prognosis more accurately, since the nomogram has been confirmed in other validation cohorts.

2. Materials and Methods {#sec2}
========================

2.1. Clinical Data of Patients {#sec2.1}
------------------------------

A total of 688 patients with gastric cancer receiving radical resection in Fudan University Cancer Hospital from 2012 to 2014 were collected as the primary cohort. Another 174 patients with gastric cancer receiving radical resection in the Third People\'s Hospital of Yancheng were enrolled as the validation cohort. In this study, all patients had gastric adenocarcinoma, and others with malignant gastric tumors, such as lymphoma, gastrointestinal stromal tumors, and gastric stump carcinoma, were excluded from this study. No patients underwent neoadjuvant chemotherapy. Moreover, patients with active infection or inflammatory diseases within 1 month before blood examination were also excluded. Patients pathologically diagnosed with T3, T4, or lymph node metastasis and high-risk factors (poorly differentiated tumors, lymphatic vascular infiltration, etc.) were treated with fluorouracil-based adjuvant chemotherapy after operation. OS was determined by the period from the time of surgery to the last follow-up or date of patient death. In the primary cohort, the median follow-up time was 36 months (1--75 months), and the number of events for OS was 383 at the last follow-up. In the validation cohort, the median follow-up time was 32 months (4--69 months), and the number of events for OS was 86 at the last follow-up. All patients signed the informed consent, all studies were performed according to the *Helsinki Declaration*, and this retrospective experiment was approved by the Ethics Committee of the Third People\'s Hospital of Yancheng.

2.2. Systemic Inflammatory Indexes {#sec2.2}
----------------------------------

Peripheral blood was collected within 1 week before the operation to detect neutrophils, lymphocytes, and platelet count. Blood cell counts were detected by Sysmex XT-1800i Automated Hematology System (Shanghai, China): NLR = neutrophil count/lymphocyte count; PLR = platelet count/lymphocyte count; MLR = monocyte count/lymphocyte count; SII = platelet count × neutrophil count/lymphocyte count. The optimal cut-off values for the above indexes were obtained using X-tile software (<https://x-tile.software.informer.com/>) \[[@B20]\]: SII (SII ≤ 320, SII \> 320), NLR (NLR ≤ 1.3, NLR \> 1.3), PLR (PLR ≤ 135, PLR \> 135), and MLR (MLR ≤ 0.23, NLR \> 0.23).

2.3. Statistical Analysis {#sec2.3}
-------------------------

SPSS 22.0 software, GraphPad Prism 5.0, and R language were used for statistical analysis. A time-dependent ROC curve was carried out using R software version 3.2.0 (<http://www.r-project.org/>) with rms and survival ROC packages. Analysis of variance and the Pearson chi-square test were used to evaluate the correlations among variables. The survival curve was plotted using the Kaplan-Meier method, and differences between groups were compared via the log-rank test. Univariate and multivariate Cox proportional hazard models were adopted to determine prognostic indexes, and the nomogram was plotted based on multivariate analysis results. Moreover, the efficiency of the nomogram was evaluated, and the time-dependent receiver operating characteristics (ROC) curve and C index were analysed to compare the discriminatory ability of different models in total survival. Unless otherwise specified, *P* \< 0.05 suggested that the difference was statistically significant.

3. Results {#sec3}
==========

3.1. Clinicopathological Features of the Patient {#sec3.1}
------------------------------------------------

In the primary cohort, there were 471 males and 217 females, aged 56 years on average, including 316 cases of tumor diameter ≤ 5 cm and 372 cases of tumor diameter \> 5 cm. There were 367 cases of high-moderate differentiation, and 321 cases of poor differentiation or no differentiation. In terms of the Lauren type, there were 328 cases of intestinal type, 115 cases of diffuse type, and 245 cases of mixed type. According to the 8th edition of the AJCC-TNM staging system, there were 183 cases in stage I, 215 cases in stage II, and 290 cases in stage III. Four hundred twenty-one patients underwent postoperative adjuvant chemotherapy, while 267 patients underwent no postoperative adjuvant chemotherapy. Other clinicopathological parameters and the validation cohort of patients are shown in [Table 1](#tab1){ref-type="table"}.

The correlation between various systemic inflammatory indexes and clinicopathological features is shown in [Table 2](#tab2){ref-type="table"}. In the primary cohort, the preoperative SII \> 320 was related to poor differentiation, upper tumor site, larger tumor, and later TNM stage. In the validation cohort, SII was also related to poor differentiation, larger tumor, and later TNM stage. Moreover, SII had strong correlations with other systemic inflammatory indexes (NLR, PLR, and MLR) in both the primary cohort and the validation cohort ([Table 2](#tab2){ref-type="table"}).

3.2. Survival Analysis {#sec3.2}
----------------------

In the primary cohort, the Kaplan-Meier survival analysis revealed that gastric cancer patients with high SII, PLR, NLR, and MLR scores had poor prognosis (Figures [1(a)](#fig1){ref-type="fig"}--[1(d)](#fig1){ref-type="fig"}), but the counts for neutrophils, lymphocytes, platelets, and monocyte alone showed no significant influences on prognosis. The relationships between survival and tumor site, histological grade, tumor size, nerve infiltration, and TNM staging were determined according to the Cox univariate analyses. SII, PLR, NLR, and MLR were factors affecting prognosis, while gender, age, Lauren type, vascular infiltration, and postoperative adjuvant chemotherapy had no significant influences on prognosis ([Table 3](#tab3){ref-type="table"}). Multivariate analysis further revealed that TNM stage and SII were independent risk factors for gastric cancer ([Table 3](#tab3){ref-type="table"}). Among SII, NLR, PLR, and MLR, only SII was an independent risk factor for OS (HR = 1.61, 95% CI: 1.27--2.05, *P* = 0.041). In addition, the ROC curve showed that the area under the curve of SII was larger than that of NLR, PLR, and MLR, indicating that SII is superior to other inflammatory indexes in predicting the 3- and 5-year survival rates of patients with gastric cancer (Figures [1(e)](#fig1){ref-type="fig"}--[1(f)](#fig1){ref-type="fig"}). Survival analysis of the validation cohort showed that patients with SII ≤ 320 had longer OS, and similar results were obtained in NLR, PLR, and MLR (Figures [2(a)](#fig2){ref-type="fig"}--[2(d)](#fig2){ref-type="fig"}). Among SII, NLR, PLR, and MLR, however, only SII was an independent prognostic index for patients with gastric cancer in the multivariate analysis (HR = 2.94, 95% CI: 1.83--4.17, *P* \< 0.001, [Table 3](#tab3){ref-type="table"}). The ROC curve showed that the area under the curve of SII was larger than that of NLR, PLR, and MLR (Figures [2(e)](#fig2){ref-type="fig"}--[2(f)](#fig2){ref-type="fig"}). To sum up, it is believed that SII is superior to other inflammatory indexes in predicting the 3- and 5-year survival rates of patients with gastric cancer.

3.3. Establishment and Verification of the Nomogram {#sec3.3}
---------------------------------------------------

Based on the multivariate analysis results, the following variables were eventually integrated in the nomogram to predict the 3- and 5-year survival of the primary cohort: TNM stage and SII ([Figure 3](#fig3){ref-type="fig"}). The C index of nomogram was 0.74, which was significantly higher than that of TNM staging 0.70 (*P* \< 0.001). The 3- and 5-year survival probability calibration charts showed that the predictive height of the nomogram was consistent with the actual observations (Figures [4(a)](#fig4){ref-type="fig"} and [4(b)](#fig4){ref-type="fig"}). Moreover, the nomogram predicted the survival of the primary cohort more accurately. The area under the ROC curve of the nomogram was significantly larger than that of TNM stage (Figures [4(c)](#fig4){ref-type="fig"} and [4(d)](#fig4){ref-type="fig"}) (*P* \< 0.001).

Finally, the established nomogram was used to verify survival in the validation cohort. The calibration curve showed that the 3- and 5-year survival rates predicted by the nomogram were consistent with the actual observation (Figures [4(e)](#fig4){ref-type="fig"} and [4(f)](#fig4){ref-type="fig"}). The C index of the nomogram was 0.72, which was significantly higher than that of TNM staging 0.69 (*P* \< 0.001). The area under the ROC curve of the nomogram in the predictive validation cohort was also significantly larger than that of the TNM stage (Figures [4(g)](#fig4){ref-type="fig"} and [4(h)](#fig4){ref-type="fig"}) (*P* \< 0.001). The above results indicate that the established nomogram, based on SII, is superior to the TNM staging system in predicting the survival of patients with gastric cancer.

4. Discussion {#sec4}
=============

In the 19^th^ century, Rudolf Vichow et al., German pathologists, found leukocytes in tumor tissues and proposed that there was a close correlation between inflammation and tumors \[[@B21]\]. With continuing research, the important correlation between inflammation and tumors has been gradually confirmed by related epidemiological and molecular biology research. According to epidemiological surveys, major clinical evidence for the connection between chronic inflammation and tumors exists. Molecular biological studies distinguish the interaction between inflammation and tumors from phenomenon and mechanisms. Tumor-related inflammatory factors include not only inflammatory factors produced by tumor cells but also tumor-related inflammatory cells and inflammatory factors released during tissue engineering, repair, and angiogenesis \[[@B10]\]. Under the status of injury or infection, the local immune system activates a large number of inflammatory cells, such as macrophages, neutrophils, mast cells, and lymphocytes. These inflammatory cells secrete a variety of cytokines, such as tumor necrosis factor (TNF), IL-6, vascular endothelial growth factor, fibroblast growth factor, platelet-derived growth factor, and extracellular matrix proteins, such as matrix metalloproteinase (MMP), elastase, neutral protease, and collagenase, forming the inflammatory microenvironment and repairing damaged tissues. However, when there is such an inflammatory microenvironment in tumor patients, a large number of inflammatory mediators that can change the stable internal environment will be released, leading to an inflammation-related cascade, tissue atrophy and destruction, and promoting malignant progression of tumors \[[@B22], [@B23]\]. The persistent inflammatory microenvironment induces tumorigenesis, and the formation and development of tumors further aggravate the inflammatory response. Therefore, systemic inflammatory response has a clear correlation with tumor prognosis, and the prognostic scoring system based on systemic inflammatory response can effectively evaluate the prognosis of cancer patients. NLR, PLR MLR, GPS, and mGPS have been proved to be effective systemic inflammatory score indexes.

In this study, the prognostic value of SII in patients with gastric cancer was studied. SII is a systemic inflammatory index based on neutrophils, platelets, and lymphocytes. Neutrophils are mainly involved in nonspecific cellular immunity of the blood, which can release a large amount of nitric oxide, arginase, and reactive oxygen species (ROS), leading to disorders of T cell activation \[[@B24]\]. Circulating neutrophils have a prognostic value in a variety of tumors, and studies confirm that patients with larger peripheral neutrophilic granulocyte count, or NLR, have a lower survival rate \[[@B25], [@B26]\]. Platelets can protect the CTC from shear stress, induce epithelial-mesenchymal transition, and promote the overflow of tumor cells to the metastatic site \[[@B8], [@B27]\]. At the same time, it has been reported that platelets and neutrophils promote adhesion and spread in distant organs through secretion of vascular endothelial growth factor \[[@B9], [@B28]\]. Lymphocytes are an important component of leukocytes produced in lymphoid organs, which are an important cellular component involved in the immune response. Lymphatic reflux in the body can make the lymph nodes receive a timely antigenic stimulation, secrete a large number of cells and humoural factors, generate specific immune response, and control tumor growth \[[@B29]\]. A decline in the number and function of lymphocytes will weaken immune surveillance and defence from cancer \[[@B29]\].

In this study, SII proved to be related to tumor location, histological grade, tumor size, TNM stage, and perineural infiltration in patients with gastric cancer and was an independent prognostic factor for patients with gastric cancer. SII has a better predictive ability than other existing prognostic indexes based on inflammation, such as NLR, PLR, and MLR. The nomogram established can accurately predict the 3- and 5-year survival rates of patients with gastric cancer after operation, and its accuracy is significantly higher than that of the 8^th^ edition AJCC staging system. There were some limitations in this study, such as selection bias and the retrospective study design. The systemic inflammatory response in the peripheral blood was not compared with local inflammation of tumors. However, the potent prognostic efficacy and convenient detection method of SII as a new systemic inflammatory score enable it to be beneficial. Many previous studies researched that systemic immune indexes can be used to predict efficacy of therapies in tumor patients \[[@B30]--[@B33]\], but we have only researched the relationship between the systemic immune indexes and gastric cancer patients\' OS. We suggested further research on the relationship between systemic immune indexes and tumor relapse. In addition, the level of these indices in relapse cases and their dynamic changes with treatment response also need to be explored. In the future, a multicentre, prospective study is needed to verify our findings.

In conclusion, this study indicates that as a novel prognostic score based on inflammation, SII can independently predict the overall survival of patients with gastric cancer after operation, which is superior to the existing systemic inflammatory indexes (NLR, PLR, and MLR) that are based on peripheral blood immunity and inflammatory cells. The prognostic nomogram based on SII is a reliable model for predicting the postoperative survival of patients with gastric cancer.
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###### 

Clinicopathological characteristics of patients with gastric cancer in the primary cohort and the validation cohort.

  Characteristic                       Primary cohort (*n* = 688)   Validation cohort (*n* = 174)         
  ------------------------------------ ---------------------------- ------------------------------- ----- ------
  Sex                                                                                                     
   Male                                471                          68.5                            131   75.3
   Female                              217                          31.5                            43    24.7
  Age                                                                                                     
   ≤60                                 463                          67.3                            103   59.2
   \>60                                225                          32.7                            71    40.8
  Tumor location                                                                                          
   Upper                               106                          15.4                            28    16.1
   Middle                              267                          38.8                            53    30.5
   Lower                               315                          45.8                            93    53.4
  Histological grade                                                                                      
   Well or moderately differentiated   367                          53.3                            100   57.5
   Poorly or not differentiated        321                          46.7                            74    42.5
  Lauren type                                                                                             
   Diffuse                             115                          16.7                            34    19.5
   Intestinal                          328                          47.7                            75    43.1
   Mixed                               245                          35.6                            65    37.4
  Tumor size                                                                                              
   ≤5                                  316                          45.9                            72    41.4
   \>5                                 372                          54.1                            102   58.6
  Lymphovascular invasion                                                                                 
   No                                  483                          70.2                            111   63.8
   Yes                                 205                          29.8                            63    36.2
  Perineural invasion                                                                                     
   No                                  392                          57.0                            122   29.9
   Yes                                 296                          43.0                            52    70.1
  TNM stage (AJCC, 8th)                                                                                   
   I                                   183                          26.6                            43    24.7
   II                                  215                          31.3                            88    50.6
   III                                 290                          42.2                            43    24.7
  Adjuvant chemotherapy                                                                                   
   No                                  267                          38.8                            62    35.6
   Yes                                 421                          61.2                            112   64.4

###### 

Baseline characteristics for patients with SII ≤ 320 versus SII \> 320 in primary and validation cohorts.

  Clinical parameter                   Primary cohort   Validation cohort                                            
  ------------------------------------ ---------------- ------------------- -------- ------------ ---- ---- -------- ------------
  Sex                                                                       0.75     0.386                  0.07     0.79
   Male                                249              222                                       67   64            
   Female                              107              110                                       23   20            
  Age                                                                       0.55     0.457                  0.01     0.932
   ≤60                                 235              228                                       53   50            
   \>60                                121              104                                       37   34            
  Tumor location                                                            16.51    \<0.001^∗^             1.35     0.51
   Upper                               36               70                                        17   11            
   Middle                              142              125                                       25   28            
   Lower                               178              137                                       48   45            
  Histological grade                                                        31.85    \<0.001^∗^             8.10     0.004^∗^
   Well or moderately differentiated   153              214                                       61   39            
   Poorly or not differentiated        203              118                                       29   45            
  Lauren type                                                               2.15     0.341                  3.05     0.218
   Diffuse                             65               50                                        17   17            
   Intestinal                          161              167                                       34   41            
   Mixed                               130              115                                       39   26            
  Tumor size                                                                55.11    \<0.001^∗^             13.50    \<0.001^∗^
   ≤5                                  212              104                                       45   27            
   \>5                                 144              228                                       35   67            
  Lymphovascular invasion                                                   1.39     0.238                  0.02     0.896
   No                                  257              226                                       57   54            
   Yes                                 99               106                                       33   30            
  Perineural invasion                                                       6.20     0.013^∗^               0.09     0.766
   No                                  219              173                                       64   58            
   Yes                                 137              159                                       26   26            
  TNM stage (AJCC, 8th)                                                     83.59    \<0.001^∗^             13.99    0.001^∗^
   I                                   119              64                                        26   17            
   II                                  146              69                                        35   53            
   III                                 91               199                                       9    34            
  Adjuvant chemotherapy                                                     0.84     0.36                   1.55     0.213
   No                                  144              123                                       36   26            
   Yes                                 212              209                                       54   58            
  NLR                                                                       140.83   \<0.001^∗^             48.38    \<0.001^∗^
   NLR ≤ 1.3                           268              100                                       51   6             
   NLR \> 1.3                          88               232                                       39   78            
  PLR                                                                       123.64   \<0.001^∗^             103.24   \<0.001^∗^
   PLR ≤ 135                           212              60                                        82   12            
   PLR \> 135                          144              272                                       8    72            
  MLR                                                                       38.74    \<0.001^∗^             21.60    \<0.001^∗^
   MLR ≤ 0.23                          226              132                                       78   46            
   MLR \> 0.23                         130              200                                       12   38            

###### 

Univariate and multivariate Cox regression analyses for overall survival in patients with gastric cancer.

  Variables                    Univariate analysis   Multivariate analysis                        
  ---------------------------- --------------------- ----------------------- -------------------- ------------
  Primary cohort                                                                                  
  Sex: male vs. female         1.14 (0.92--1.41)     0.223                                        
  Age: \>60 vs. ≤60            1.24 (0.99--1.54)     0.053                                        
  Tumor location                                     0.001^∗^                                     0.057
   Middle vs. upper            0.71 (0.54--0.93)     0.018^∗^                0.84 (0.63--1.12)    0.227
   Lower vs. upper             0.58 (0.44--0.76)     \<0.001^∗^              0.71 (0.53--0.95)    0.020^∗^
  Grade: poorly vs. well       0.56 (0.40--0.72)     \<0.001^∗^              1.12 (0.89--1.41)    0.350
  Lauren type                                        0.137                                        
   Intestinal vs. diffuse      1.21 (0.91--1.62)     0.195                                        
   Mixed vs. diffuse           0.98 (0.72--1.34)     0.907                                        
  Tumor size: \>5 vs. ≤5       2.38 (1.92--2.94)     \<0.001^∗^              1.19 (0.94--1.51)    0.142
  Lymphovascular: yes vs. no   1.21 (0.97--1.50)     0.086                                        
  Perineural: yes vs. no       1.58 (1.29--1.93)     \<0.001^∗^              1.21 (0.96--1.53)    0.101
  TNM stage                                          \<0.001^∗^                                   \<0.001^∗^
   II vs. I                    2.03 (1.46--2.83)     \<0.001^∗^              1.77 (1.26--2.47)    0.001^∗^
   III vs. I                   4.68 (3.46--6.34)     \<0.001^∗^              3.10 (2.27--4.24)    \<0.001^∗^
  Chemotherapy: Yes vs. No     1.12 (0.91--1.37)     0.282                                        
  SII: \>320 vs. ≤320          2.47 (2.01--3.04)     \<0.001^∗^              1.61 (1.27--2.05)    0.041^∗^
  NLR: \>1.3 vs. ≤1.3          1.79 (1.47--2.20)     \<0.001^∗^              1.25 (0.99--1.58)    0.054
  PLR: \>135 vs. ≤135          1.82 (1.46--2.27)     \<0.001^∗^              1.04 (0.81--1.33)    0.787
  MLR: \>0.23 vs. ≤0.23        1.88 (1.54--2.31)     \<0.001^∗^              1.17 (0.93--1.47)    0.183
  Validation cohort                                                                               
  Sex: male vs. female         1.01 (0.62--1.63)     0.987                                        
  Age: \>60 vs. ≤60            1.09 (0.88--1.36)     0.442                                        
  Tumor location                                     0.046^∗^                                     0.098
   Middle vs. upper            0.51 (0.29--0.89)     0.018^∗^                0.61 (0.30--1.41)    0.146
   Lower vs. upper             0.51 (0.27--0.94)     0.032^∗^                0.65 (0.38--1.10)    0.087
  Grade: poorly vs. well       1.25 (1.01--1.54)     0.041^∗^                1.48 (0.95--2.29)    0.080
  Lauren type                                        0.386                                        
   Intestinal vs. diffuse      0.65 (0.34--1.25)     0.196                                        
   Mixed vs. diffuse           0.99 (0.63--1.57)     0.979                                        
  Tumor size: \>5 vs. ≤5       1.72 (1.09--2.70)     0.019^∗^                1.81 (0.81--4.04)    0.151
  Lymphovascular: yes vs. no   1.48 (0.90--2.43)     0.118                                        
  Perineural: yes vs. no       1.70 (1.06--2.72)     0.028^∗^                1.43 (0.61--3.39)    0.414
  TNM stage                                          \<0.001^∗^                                   \<0.001^∗^
   II vs. I                    2.91 (1.45--5.83)     0.003^∗^                3.19 (1.43--3.63)    0.002^∗^
   III vs. I                   7.12 (3.50--14.50)    \<0.001^∗^              7.05 (3.15--15.81)   \<0.001^∗^
  Chemotherapy: yes vs. no     1.26 (0.79--2.01)     0.001^∗^                                     
  SII: \>320 vs. ≤320          2.75 (1.75--4.32)     \<0.001^∗^              2.94 (1.83--4.73)    \<0.001^∗^
  NLR: \>1.3 vs. ≤1.3          2.03 (1.23--3.35)     0.006^∗^                1.71 (0.96--3.39)    0.067
  PLR: \>135 vs. ≤135          1.90 (1.24--2.94)     0.004^∗^                1.46 (0.93--2.30)    0.102
  MLR: \>0.23 vs. ≤0.23        1.56 (1.02--2.40)     0.046^∗^                1.22 (0.76--1.95)    0.420
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